diazoxide has been researched along with Heart Failure in 24 studies
Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.
diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Angiotensin II (Ang II) and tumour necrosis factor alpha (TNFalpha) are involved in the progression from compensated hypertrophy to heart failure." | 7.75 | Angiotensin II and tumour necrosis factor alpha as mediators of ATP-dependent potassium channel remodelling in post-infarction heart failure. ( Baertschi, AJ; Isidoro Tavares, N; Lerch, R; Montessuit, C; Philip-Couderc, P, 2009) |
| "Diazoxide is a non-diuretic benzothiadiazine derivative, one of a group of substances introduced into clinical practice in the 1950s for the treatment of hypertension." | 5.43 | Safety and tolerability of diazoxide in Japanese patients with hyperinsulinemic hypoglycemia. ( Inoue, Y; Komatsu, Y; Miyoshi, H; Nakamura, A; Tajima, K; Takano, T; Takihata, M; Terauchi, Y; Tsuchiya, H; Yahagi, S; Yamakawa, T; Yoshida, M, 2016) |
| "Diazoxide treatment remains the mainstay of medical therapy." | 5.35 | Pulmonary hypertension, heart failure and neutropenia due to diazoxide therapy. ( Erdem, S; Küçükosmanoglu, O; Yildizdas, D; Yilmaz, M; Yüksel, B, 2008) |
| "Cardiorespiratory failure (toxicity) occurred on eight of the 11 occasions (73%) in seven infants." | 5.28 | Complications of diazoxide treatment in persistent neonatal hyperinsulinism. ( Abu-Osba, YK; Manasra, KB; Mathew, PM, 1989) |
| "Diazoxide was administered intravenously in successive 300 mg infusions, each over 10 minutes, until a satisfactory response in cardiac and output occurred or a fall in arterial blood pressure or increase in heart rate was noted." | 5.26 | Beneficial hemodynamic effects of intravenous diazoxide in refractory congestive heart failure. ( Hanlon, JT; Haughom, F; Massie, BM; Stern, R, 1982) |
| "Angiotensin II (Ang II) and tumour necrosis factor alpha (TNFalpha) are involved in the progression from compensated hypertrophy to heart failure." | 3.75 | Angiotensin II and tumour necrosis factor alpha as mediators of ATP-dependent potassium channel remodelling in post-infarction heart failure. ( Baertschi, AJ; Isidoro Tavares, N; Lerch, R; Montessuit, C; Philip-Couderc, P, 2009) |
| "Diazoxide is a non-diuretic benzothiadiazine derivative, one of a group of substances introduced into clinical practice in the 1950s for the treatment of hypertension." | 1.43 | Safety and tolerability of diazoxide in Japanese patients with hyperinsulinemic hypoglycemia. ( Inoue, Y; Komatsu, Y; Miyoshi, H; Nakamura, A; Tajima, K; Takano, T; Takihata, M; Terauchi, Y; Tsuchiya, H; Yahagi, S; Yamakawa, T; Yoshida, M, 2016) |
| "Diazoxide is an effective and usually safe medication to treat this type and other types of neonatal HI." | 1.42 | Liver injury may increase the risk of diazoxide toxicity: a case report. ( Garibaldi, L; Mahmood, B; Sperling, M; Tas, E, 2015) |
| "Glibenclamide (10 μM) terminated these arrhythmias and restored APDs to control values." | 1.37 | Effects of KATP channel openers diazoxide and pinacidil in coronary-perfused atria and ventricles from failing and non-failing human hearts. ( Ambrosi, CM; Chang, R; Efimov, IR; Fedorov, VV; Glukhov, AV; Janks, D; Kostecki, G; Moazami, N; Nichols, CG; Schuessler, RB, 2011) |
| "Diazoxide treatment remains the mainstay of medical therapy." | 1.35 | Pulmonary hypertension, heart failure and neutropenia due to diazoxide therapy. ( Erdem, S; Küçükosmanoglu, O; Yildizdas, D; Yilmaz, M; Yüksel, B, 2008) |
| "Diazoxide treatment remains the mainstay of medical therapy." | 1.32 | A case of severe diazoxide toxicity. ( Camporesi, A; Mandelli, A; Salvo, I; Silvani, P; Wolfler, A, 2004) |
| "Cardiorespiratory failure (toxicity) occurred on eight of the 11 occasions (73%) in seven infants." | 1.28 | Complications of diazoxide treatment in persistent neonatal hyperinsulinism. ( Abu-Osba, YK; Manasra, KB; Mathew, PM, 1989) |
| "They suffered serious side effects of cardiac failure and truncal ataxia." | 1.27 | Complications of diazoxide in the treatment of nesidioblastosis. ( McGraw, ME; Price, DA, 1985) |
| "Diazoxide was administered intravenously in successive 300 mg infusions, each over 10 minutes, until a satisfactory response in cardiac and output occurred or a fall in arterial blood pressure or increase in heart rate was noted." | 1.26 | Beneficial hemodynamic effects of intravenous diazoxide in refractory congestive heart failure. ( Hanlon, JT; Haughom, F; Massie, BM; Stern, R, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (70.83) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (12.50) | 29.6817 |
| 2010's | 4 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brennan, S | 1 |
| Jackson, R | 1 |
| Patel, M | 1 |
| Sims, MW | 1 |
| Hudman, D | 1 |
| Norman, RI | 1 |
| Lodwick, D | 1 |
| Rainbow, RD | 1 |
| Tas, E | 1 |
| Mahmood, B | 1 |
| Garibaldi, L | 1 |
| Sperling, M | 1 |
| Komatsu, Y | 1 |
| Nakamura, A | 1 |
| Takihata, M | 1 |
| Inoue, Y | 1 |
| Yahagi, S | 1 |
| Tajima, K | 1 |
| Tsuchiya, H | 1 |
| Takano, T | 1 |
| Yamakawa, T | 1 |
| Yoshida, M | 1 |
| Miyoshi, H | 1 |
| Terauchi, Y | 1 |
| Yildizdas, D | 1 |
| Erdem, S | 1 |
| Küçükosmanoglu, O | 1 |
| Yilmaz, M | 1 |
| Yüksel, B | 1 |
| Isidoro Tavares, N | 1 |
| Philip-Couderc, P | 1 |
| Baertschi, AJ | 1 |
| Lerch, R | 1 |
| Montessuit, C | 1 |
| Fedorov, VV | 1 |
| Glukhov, AV | 1 |
| Ambrosi, CM | 1 |
| Kostecki, G | 1 |
| Chang, R | 1 |
| Janks, D | 1 |
| Schuessler, RB | 1 |
| Moazami, N | 1 |
| Nichols, CG | 1 |
| Efimov, IR | 1 |
| Silvani, P | 1 |
| Camporesi, A | 1 |
| Mandelli, A | 1 |
| Wolfler, A | 1 |
| Salvo, I | 1 |
| Finnerty, FA | 5 |
| Davidov, M | 3 |
| Kakaviatos, N | 2 |
| Fischer, E | 1 |
| Siegenthaler, W | 1 |
| Brandt, D | 2 |
| Massie, BM | 1 |
| Stern, R | 1 |
| Hanlon, JT | 1 |
| Haughom, F | 1 |
| Sterz, H | 1 |
| Romankiewicz, JA | 1 |
| Kossmann, CE | 1 |
| Abu-Osba, YK | 1 |
| Manasra, KB | 1 |
| Mathew, PM | 1 |
| McGraw, ME | 1 |
| Price, DA | 1 |
| Gillies, DR | 1 |
| Fernandes, M | 1 |
| Kim, KE | 1 |
| Moyer, JH | 1 |
| Mauer, SM | 1 |
| Mirkin, BL | 1 |
| Mroczek, WJ | 1 |
| Gavrilovich, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use for Diazoxide in the Initial Management of Hypoglycemia in Infants of Diabetic Mothers and Infants Large for Gestation[NCT00994149] | Phase 2/Phase 3 | 100 participants (Anticipated) | Interventional | 2009-10-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for diazoxide and Heart Failure
| Article | Year |
|---|---|
[Therapy of hypertensive crisis].
Topics: Acute Disease; Bed Rest; Cardiac Glycosides; Clonidine; Diazoxide; Dihydralazine; Diuretics; Heart F | 1980 |
[New aspects in the treatment of acute cardiac insufficiency].
Topics: Adrenergic beta-Antagonists; Clonidine; Diazoxide; Digitalis Glycosides; Diuretics; Droperidol; Fent | 1978 |
Pharmacology and clinical use of drugs in hypertensive emergencies.
Topics: Adrenal Gland Neoplasms; Antihypertensive Agents; Aorta; Brain Diseases; Cerebral Hemorrhage; Diazox | 1977 |
Hypertensive emergencies.
Topics: Acute Kidney Injury; Adrenal Gland Neoplasms; Antihypertensive Agents; Aortic Aneurysm; Blood Volume | 1974 |
20 other studies available for diazoxide and Heart Failure
| Article | Year |
|---|---|
Early opening of sarcolemmal ATP-sensitive potassium channels is not a key step in PKC-mediated cardioprotection.
Topics: Action Potentials; Adenosine; Animals; Cardiotonic Agents; Cell Separation; Diazoxide; Enzyme Activa | 2015 |
Liver injury may increase the risk of diazoxide toxicity: a case report.
Topics: Albumins; Blood Glucose; Chemical and Drug Induced Liver Injury; Diazoxide; Heart Failure; Humans; H | 2015 |
Safety and tolerability of diazoxide in Japanese patients with hyperinsulinemic hypoglycemia.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Diazoxide; Drug Monitoring; Drug Resistance; Edema | 2016 |
Pulmonary hypertension, heart failure and neutropenia due to diazoxide therapy.
Topics: Congenital Hyperinsulinism; Diazoxide; Female; Heart Failure; Humans; Hypertension, Pulmonary; Infan | 2008 |
Angiotensin II and tumour necrosis factor alpha as mediators of ATP-dependent potassium channel remodelling in post-infarction heart failure.
Topics: Action Potentials; Angiotensin II; Animals; ATP-Binding Cassette Transporters; Cells, Cultured; Diaz | 2009 |
Effects of KATP channel openers diazoxide and pinacidil in coronary-perfused atria and ventricles from failing and non-failing human hearts.
Topics: Action Potentials; Adolescent; Adult; Arrhythmias, Cardiac; Coronary Vessels; Diazoxide; Female; Gen | 2011 |
A case of severe diazoxide toxicity.
Topics: Blood Glucose; Diazoxide; Edema; Heart Failure; Humans; Hyperinsulinism; Infant; Male; Pancreatectom | 2004 |
Hypertensive vascular disease. The long term effect of rapid repeated reductions of arterial pressure with diazoxide.
Topics: Adult; Chlorthalidone; Diazoxide; Female; Heart Failure; Humans; Hydralazine; Hypertension; Injectio | 1967 |
[Vasodilators in heart failure? Basic principles and its role in practice].
Topics: Adrenergic alpha-Antagonists; Captopril; Diazoxide; Furosemide; Heart Failure; Humans; Hydralazine; | 1981 |
[The hypertensive crisis].
Topics: Acute Disease; Calcium Channel Blockers; Clonidine; Coronary Disease; Diazoxide; Dihydralazine; Dilt | 1984 |
Beneficial hemodynamic effects of intravenous diazoxide in refractory congestive heart failure.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Cardiac Volume; Diazoxide; Heart Failure; Hemodynamics; | 1982 |
Contraindications to digitalis in congestive "heart" failure.
Topics: Diazoxide; Digitalis Glycosides; Furosemide; Heart Failure; Humans; Hypertension; Male; Methyldopa; | 1977 |
Complications of diazoxide treatment in persistent neonatal hyperinsulinism.
Topics: Blood Glucose; Diazoxide; Female; Heart Failure; Humans; Hyperinsulinism; Hypoglycemia; Infant; Insu | 1989 |
Complications of diazoxide in the treatment of nesidioblastosis.
Topics: Ataxia; Diazoxide; Heart Failure; Humans; Infant; Infant, Newborn; Male; Pancreatic Diseases | 1985 |
Complications of diazoxide in the treatment of nesidioblastosis.
Topics: Diazoxide; Female; Heart Failure; Humans; Infant, Newborn; Pancreatic Diseases | 1985 |
Aggressive drug therapy in accelerated hypertension.
Topics: Antihypertensive Agents; Aortic Aneurysm; Brain Diseases; Cerebrovascular Disorders; Diazoxide; Ferr | 1974 |
Treatment of hypertension in infancy with diazoxide: report of a case with arrhythmia as a complications of therapy.
Topics: Arrhythmias, Cardiac; Blood Pressure; Coronary Disease; Diazoxide; Female; Heart Failure; Humans; Hy | 1972 |
The long term effect of repeated acute reductions of arterial pressure with diazoxide in patients with severe hypertension.
Topics: Acidosis; Blood Glucose; Diazoxide; Heart; Heart Failure; Humans; Hyperaldosteronism; Hypertension; | 1968 |
The value of aggressive therapy in the hypertensive patient with azotemia.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Arteries; Blood Pressure; Blood Urea Nitrogen; | 1969 |
Failure of repeated diazoxide injections to modify the course of severe hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diazoxide; Diuretics; Guanethidine; Heart F | 1971 |